Doubling Down On Cardiac Regeneration, AstraZeneca Forms Research Alliance With Shanghai SIBS
This article was originally published in PharmAsia News
Executive Summary
Going deeper into the cardiac regeneration space, AstraZeneca signed an agreement with SIBS to research coronary artery regeneration.